Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-escalating pasireotide for progressive non-functional gastroenteropancreatic neuroendocrine tumors after octreotide
ACTRN12615001328561Phase 2Not yet recruiting
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Dec 2015
- Modality
- Small Molecules, Peptides
01
Overview
Phase 2, open-label, single-arm trial of pasireotide LAR in Gastroenteropancreatic Carcinoid Tumor, sponsored by Peter MacCallum Cancer Centre. Primary endpoint: Progression-free survival at 96 weeks. Planned start Dec 2015; status: not yet recruiting.
02
Drugs
pasireotide LAR
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on ACTRN12615001328561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615001328561.